Back to Search Start Over

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

Authors :
Usmani, Saad Z
Nahi, Hareth
Plesner, Torben
Weiss, Brendan M
Bahlis, Nizar J
Belch, Andrew
Voorhees, Peter M
Laubach, Jacob P
van de Donk, Niels W C J
Ahmadi, Tahamtan
Uhlar, Clarissa M
Wang, Jianping
Feng, Huaibao
Qi, Ming
Richardson, Paul G
Lonial, Sagar
Source :
The Lancet Haematology; June 2020, Vol. 7 Issue: 6 pe447-e455, 9p
Publication Year :
2020

Abstract

Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a pooled, post-hoc final analysis of these two studies.

Details

Language :
English
ISSN :
23523026
Volume :
7
Issue :
6
Database :
Supplemental Index
Journal :
The Lancet Haematology
Publication Type :
Periodical
Accession number :
ejs54439934
Full Text :
https://doi.org/10.1016/S2352-3026(20)30081-8